Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
caffeine + epigallocatechin gallate
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral, Topical
01
Overview
A combination of caffeine and epigallocatechin gallate (EGCG), a major catechin found in green tea, investigated for its potential in weight management and thermogenesis. The mixture works synergistically to increase energy expenditure and fat oxidation. Caffeine acts as a phosphodiesterase inhibitor and an adenosine receptor antagonist, which stimulates the sympathetic nervous system and increases norepinephrine release. EGCG inhibits catechol-O-methyltransferase (COMT), the enzyme responsible for degrading norepinephrine. By combining these mechanisms, the mixture prolongs the thermogenic effects of norepinephrine, aiding in body weight loss and the maintenance of weight loss, particularly in individuals with low habitual caffeine intake.
- Brand names
- teavigo
- Other names
- caffeine + epigallocatechin gallateEGCG + caffeinegreen tea-caffeine mixtureepigallocatechin-3-gallate + caffeine
02
Targets
ADOR (Adenosine receptors)PYG (Glycogen phosphorylase)
Beyond the preview
Go deeper on caffeine + epigallocatechin gallate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on caffeine + epigallocatechin gallate.